AbbVie's hepatitis C regimen wins breakthrough designation from FDA

05/7/2013 | Chicago Tribune (tiered subscription model) · RTT News

The FDA granted breakthrough therapy status to AbbVie's experimental direct-acting antiviral regimen, with and without ribavirin, as a therapy for genotype 1 hepatitis C virus. The combo is in late-stage trials in 29 nations.

View Full Article in:

Chicago Tribune (tiered subscription model) · RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Meridian Health Plan
Detroit, MI